
Tumor PDO 2.0
An ALI-based tumor model for studying treatment response alongside source-tissue architecture and immune cells retained from the sample.
Models & products
Compare tumor PDOs, normal-tissue organoids and disease models by project goal, available assays and collaboration format. Browse options for supplied models, TRiCBIO-run studies and custom development.
Start from a common study combination or select up to three models.
Choosing PDO 1.0 or PDO 2.07 models shown
0 of 3 models selected for comparison

An ALI-based tumor model for studying treatment response alongside source-tissue architecture and immune cells retained from the sample.

Patient-derived breast tumor organoids for single-agent and combination studies, with PDO 2.0 / ALI considered when immune context is relevant.

Established from primary or metastatic colorectal tumors to compare drug response, tissue features and inter-sample differences.

Use conventional PDOs for HCC efficacy studies. Immunotherapy or anti-angiogenic programs can add PDO 2.0, vascular-marker profiling or a purpose-built co-culture.

A renal cancer PDO system for evaluating responses to targeted and immune therapies using apoptosis and immune-cell activation readouts.

Use conventional PDOs for pancreatic epithelial and drug-response studies, with ALI or custom co-culture added when stromal or immune context is important.

Case-specific model development, phenotype profiling and candidate-response studies for GIST, osteosarcoma and related tumors.
PRODUCT CATALOG

A starter kit for PDO 2.0 / ALI recovery and initial culture, with protocol guidance and technical support.

Core reagents for teams with ALI experience or preparing to establish a routine PDO 2.0 culture workflow.

For primary sample processing, organoid establishment, expansion and passaging, with gentle dissociation and workflow guidance matched to the sample.

Configured around model type, cryopreservation scale and post-thaw QC for organoid storage, recovery and biobanking.

For TME-associated cell profiling by flow cytometry or immunofluorescence, with antibody panels matched to the model and assay platform.
Models & products
Compare tumor PDOs, normal-tissue organoids and disease models by project goal, available assays and collaboration format. Browse options for supplied models, TRiCBIO-run studies and custom development.
Start from a common study combination or select up to three models.
Choosing PDO 1.0 or PDO 2.07 models shown
0 of 3 models selected for comparison

An ALI-based tumor model for studying treatment response alongside source-tissue architecture and immune cells retained from the sample.

Patient-derived breast tumor organoids for single-agent and combination studies, with PDO 2.0 / ALI considered when immune context is relevant.

Established from primary or metastatic colorectal tumors to compare drug response, tissue features and inter-sample differences.

Use conventional PDOs for HCC efficacy studies. Immunotherapy or anti-angiogenic programs can add PDO 2.0, vascular-marker profiling or a purpose-built co-culture.

A renal cancer PDO system for evaluating responses to targeted and immune therapies using apoptosis and immune-cell activation readouts.

Use conventional PDOs for pancreatic epithelial and drug-response studies, with ALI or custom co-culture added when stromal or immune context is important.

Case-specific model development, phenotype profiling and candidate-response studies for GIST, osteosarcoma and related tumors.
PRODUCT CATALOG

A starter kit for PDO 2.0 / ALI recovery and initial culture, with protocol guidance and technical support.

Core reagents for teams with ALI experience or preparing to establish a routine PDO 2.0 culture workflow.

For primary sample processing, organoid establishment, expansion and passaging, with gentle dissociation and workflow guidance matched to the sample.

Configured around model type, cryopreservation scale and post-thaw QC for organoid storage, recovery and biobanking.

For TME-associated cell profiling by flow cytometry or immunofluorescence, with antibody panels matched to the model and assay platform.